Adverse Effects of Statin Therapy
Introduction
- Statin therapy is associated with various adverse effects, including hepatic, musculoskeletal, and drug interactions, as reported by the American College of Cardiology 1
Hepatic Effects
- Elevated liver enzymes occur in 0.5-2.0% of patients, are dose-dependent, usually asymptomatic, and typically reversible with dose reduction, with progression to liver failure being exceedingly rare 1, 2
- The American College of Cardiology recommends measuring ALT levels before starting statin therapy and considering baseline CK measurement in high-risk patients 1, 3
- Monitor for symptoms of hepatotoxicity and check liver function if they arise, as recommended by the American College of Cardiology 3
Musculoskeletal Effects
- Statin-associated muscle symptoms (SAMS) occur in 5-10% of patients, with risk factors including age, female sex, low body mass index, high-risk medications, comorbidities, Asian ancestry, excess alcohol, high levels of physical activity, and trauma, as identified by the American College of Cardiology 4, 1
- Severe muscle effects, such as myositis/myopathy, rhabdomyolysis, and statin-associated autoimmune myopathy, are rare but can occur, as reported by the American College of Cardiology 4
- CK measurement is advised if severe muscle symptoms or objective weakness develops, and consider temporary discontinuation until symptoms improve, as recommended by the American College of Cardiology 4, 1
Drug Interactions
- Drug interactions, especially with medications metabolized by cytochrome P450, can increase the risk of side effects, as reported by the American College of Cardiology 1
- Advanced age (especially over 80 years), female sex, small body frame and frailty, multiple comorbidities, multiple medications, perioperative periods, and Asian ancestry are risk factors for statin-related complications, as identified by the American College of Cardiology 1
- Statins are contraindicated during pregnancy, and the American College of Cardiology suggests considering withholding statins during hospitalization for major surgery due to perioperative risk 1
Special Considerations
- The American College of Cardiology recommends continuing statin therapy despite increased risk of new-onset diabetes mellitus, emphasizing lifestyle modifications 4, 2, 1
- Rechallenging with the same or different statin, reduced dosing, or alternate-day dosing has proven effective for 92.2% of patients initially intolerant to statins, as reported by 5
- The American College of Cardiology recommends measuring CK in patients with severe symptoms or objective weakness, considering temporary discontinuation until symptoms improve, and rechallenging with a lower dose, alternative statin, or alternative dosing regimen 4
Statin Selection
- All currently marketed statins have a similar potential for causing severe myopathy (0.08-0.09%), though the risk of subjective myalgia varies between agents, as noted by the American College of Cardiology 1
- The American College of Cardiology suggests considering fluvastatin or pravastatin (traditionally considered to have lower myalgia risk) if pitavastatin is not tolerated or unavailable, and using the lowest effective dose 1
- The prevalence of pitavastatin intolerance is similar to placebo, according to the International Lipid Expert Panel (ILEP) 6
- In the REPRIVE trial involving 7,769 participants with HIV infection, muscle-related symptoms occurred in 2.3% of patients in the pitavastatin group compared to 1.4% in the placebo group, as reported by 6
| Statin | Risk of Severe Myopathy | Risk of Subjective Myalgia |
|---|---|---|
| All currently marketed statins | 0.08-0.09% | varies between agents |
| Pitavastatin | similar to placebo | 2.3% in the REPRIVE trial |
| Fluvastatin | traditionally considered lower | - |
| Pravastatin | traditionally considered lower | - |